0000000000311439

AUTHOR

Ambra Campofelice

showing 4 related works from this author

Functionalized halloysite nanotubes: Efficient carrier systems for antifungine drugs

2018

Abstract Halloysite-cyclodextrin hybrid was employed as carrier for sustained release of clotrimazole for vaginal or buccal treatment of Candidiasis. The nanocarrier was obtained by functionalization of halloysite surface with cyclodextrin moieties by means of microwave irradiation, with the final goal to obtain a scaffold for the covalent linkage of cysteamine hydrochloride. The interaction between clotrimazole and the pristine components, namely cyclodextrin and halloysite, was thoroughly investigated by several techniques such as DSC, TGA, UV–vis spectroscopy and some adsorption studies were, also, carried out. The release of the antifungine molecule was finally investigated in a medium …

02 engineering and technologyengineering.material010402 general chemistry01 natural sciencesHalloysiteAdsorptionGeochemistry and PetrologymedicineMoleculeSettore CHIM/02 - Chimica Fisicachemistry.chemical_classificationCyclodextrinClotrimazoletechnology industry and agricultureFunctionalized halloysite Cyclodextrin Clotrimazole Drug carrierGeologySettore CHIM/06 - Chimica Organica021001 nanoscience & nanotechnology0104 chemical scienceschemistryChemical engineeringCovalent bondengineeringSurface modificationlipids (amino acids peptides and proteins)Nanocarriers0210 nano-technologymedicine.drugApplied Clay Science
researchProduct

Strategies against nonsense: oxadiazoles as translational readthrough-inducing drugs (TRIDs)

2019

This review focuses on the use of oxadiazoles as translational readthrough-inducing drugs (TRIDs) to rescue the functional full-length protein expression in mendelian genetic diseases caused by nonsense mutations. These mutations in specific genes generate premature termination codons (PTCs) responsible for the translation of truncated proteins. After a brief introduction on nonsense mutations and their pathological effects, the features of various classes of TRIDs will be described discussing differences or similarities in their mechanisms of action. Strategies to correct the PTCs will be presented, particularly focusing on a new class of Ataluren-like oxadiazole derivatives in comparison …

0301 basic medicinemedia_common.quotation_subjectNonsenseNonsense mutationRegulatorSettore BIO/11 - Biologia MolecolareReviewComputational biologyBiologyOxadiazoleCatalysiscystic fibrosislcsh:ChemistryInorganic Chemistry03 medical and health sciences0302 clinical medicineAtalurenTranslational readthrough inducing drugsPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologyGeneSpectroscopymedia_commonNonsense mutationOrganic ChemistryTranslational readthroughoxadiazolesPremature termination codonTranslation (biology)General MedicineSettore CHIM/06 - Chimica OrganicaSmall moleculeSettore CHIM/08 - Chimica FarmaceuticaTransmembrane proteinComputer Science ApplicationsSettore BIO/18 - Genetica030104 developmental biologyPharmaceutical Preparationslcsh:Biology (General)lcsh:QD1-999Codon NonsenseProtein Biosynthesis030220 oncology & carcinogenesisCystic fibrosi
researchProduct

Uno studio comparativo in silico sui possibili target di Ataluren e analoghi farmaci promotori di readthrough di codoni di stop prematuri

2019

E’ noto in letteratura che Ataluren (acido 5-(fluorofenil)-1,2,4-ossadiazolil-benzoico) sia in grado di sopprimere le mutazioni non senso favorendo il readthrough dei codoni di stop prematuri, anche se il suo meccanismo di azione non risulta ancora chiaro. La probabile interazione tra Ataluren e CTFR-mRNA è stata precedentemente studiata mediante dinamica molecolare. In questo studio1, abbiamo esteso il modeling del probabile meccanismo di azione di Ataluren mediante approcci computazionali completementari, quali Induced Fit Docking (IFD), Quantum Polarized Ligand Docking (QPLD), metodi MM-GBSA e mutagenesi computazionale. Oltre a considerare il CTFR-mRNA, sono stati presi in considerazione…

in silico readthrough CFTR Fibrosi cistica Ataluren
researchProduct

Pharmacophore-Based Design of New Chemical Scaffolds as Translational Readthrough-Inducing Drugs (TRIDs)

2020

[Image: see text] Translational readthrough-inducing drugs (TRIDs) rescue the functional full-length protein expression in genetic diseases, such as cystic fibrosis, caused by premature termination codons (PTCs). Small molecules have been developed as TRIDs to trick the ribosomal machinery during recognition of the PTC. Herein we report a computational study to identify new TRID scaffolds. A pharmacophore approach was carried out on compounds that showed readthrough activity. The pharmacophore model applied to screen different libraries containing more than 87000 compounds identified four hit-compounds presenting scaffolds with diversity from the oxadiazole lead. These compounds have been s…

010405 organic chemistryChemistryOrganic ChemistryTranslational readthroughNonsense mutationHTVSnonsense mutationOxadiazoleBenzoxazoleRibosomal RNA01 natural sciencesBiochemistrySmall molecule0104 chemical sciencescystic fibrosis010404 medicinal & biomolecular chemistrychemistry.chemical_compoundBiochemistryDrug Discoverypremature termination codonsPharmacophoreDerivative (chemistry)Pharmacophore modeling
researchProduct